DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring systems for use by people with diabetes and by healthcare providers. Co.'s products include: DecCom G6®, which is designed to allow Co.'s transmitter to run an algorithm to generate a glucose value and to communicate directly to a patient's mobile device; and DexCom Share®, which transmits glucose information to the cloud and then to apps on the mobile devices to designated recipients, or followers, who can remotely monitor a patient's glucose information and receive alert notifications when they have a wireless connection. The DXCM stock yearly return is shown above.
The yearly return on the DXCM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DXCM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|